---
title: "Aprea Therapeutics, Inc. (APRE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/APRE.US.md"
symbol: "APRE.US"
name: "Aprea Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T21:36:04.996Z"
locales:
  - [en](https://longbridge.com/en/quote/APRE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/APRE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/APRE.US.md)
---

# Aprea Therapeutics, Inc. (APRE.US)

## Company Overview

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [aprea.com](https://aprea.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: D (0.67)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 309 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -90.40% |  |
| Net Profit YoY | 15.10% |  |
| P/B Ratio | 0.24 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10127842.28 |  |
| Revenue | 123296.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -41.85% | E |
| Profit Margin | -9696.04% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | -90.40% | E |
| Net Profit YoY | 15.10% | C |
| Total Assets YoY | 135.45% | A |
| Net Assets YoY | 150.97% | A |
| Cash Flow Margin | 100.55% | C |
| OCF YoY | -90.40% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 11.12% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Aprea Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-90.40%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "15.10%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.24",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "10127842.28",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "123296.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-41.85%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-9696.04%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-90.40%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "15.10%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "135.45%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "150.97%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "100.55%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-90.40%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "11.12%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.85 | 169/386 | - | - | - |
| PB | 0.24 | 11/386 | 0.68 | 0.62 | 0.54 |
| PS (TTM) | 82.14 | 249/386 | 14.35 | 10.87 | 8.01 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Overweight | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.78 |
| Highest Target | 6.00 |
| Lowest Target | 1.20 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/APRE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/APRE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/APRE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/APRE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**